Clinical pharmacology facing the real-world setting: Pharmacovigilance, pharmacoepidemiology and the economic evaluation of drugs.

Adverse drug reaction Effectiveness Efficiency Health technology assessment Pharmacoeconomics Pharmacoepidemiology Pharmacovigilance Real world evidence

Journal

Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 10 08 2023
revised: 15 10 2023
accepted: 18 10 2023
medline: 21 11 2023
pubmed: 22 10 2023
entrez: 21 10 2023
Statut: ppublish

Résumé

Traditionally, clinical pharmacology has focused its activities on drug-organism interaction, from an individual or collective perspective. Drug efficacy assessment by performing randomized clinical trials and analysis of drug use in clinical practice by carrying out drug utilization studies have also been other areas of interest. From now on, Clinical pharmacology should move from the analysis of the drug-individual interaction to the analysis of the drug-individual-society interaction. It should also analyze the clinical and economic consequences of the use of drugs in the conditions of normal clinical practice, beyond clinical trials. The current exponential technological development that facilitates the analysis of real-life data offers us a golden opportunity to move to all these other areas of interest. This review describes the role that clinical pharmacology has played at the beginning and during the evolution of pharmacovigilance, pharmacoepidemiology and economic drug evaluations in Spain. In addition, the challenges that clinical pharmacology is going to face in the following years in these three areas are going to be outlined too.

Identifiants

pubmed: 37865127
pii: S1043-6618(23)00323-7
doi: 10.1016/j.phrs.2023.106967
pii:
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106967

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Antonia Agustí (A)

Clinical Pharmacology Service, Vall Hebron University Hospital and Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.

Gloria Cereza (G)

Catalan Centre of Pharmacovigilance. Directorate-General for Healthcare Planning and Regulation, Ministry of Health, Government of Catalonia, and Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.

Francisco J de Abajo (FJ)

Department of Biomedical Sciences, University of Alcalá (IRYCIS) and Unit of Clinical Pharmacology, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.

Miguel A Maciá (MA)

Division of Pharmacoepidemology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices, Spain.

José A Sacristán (JA)

Medical Department, Lilly Spain, Spain. Electronic address: sacristan_jose@lilly.com.

Articles similaires

Humans Pharmaceutical Preparations Drug Utilization Prescription Drugs
Humans Cost-Benefit Analysis Brain Neoplasms Male Female
Humans Cost-Benefit Analysis Tuberculosis Medication Adherence Digital Technology

Classifications MeSH